About: Feasibility of conditioning with thymoglobulin and reduced intensity TBI to reduce acute GVHD in recipients of allogeneic SCT

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Feasibility of conditioning with thymoglobulin and reduced intensity TBI to reduce acute GVHD in recipients of allogeneic SCT Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Feasibility of conditioning with thymoglobulin and reduced intensity TBI to reduce acute GVHD in recipients of allogeneic SCT
Creator	Smith, S Bauml, M Bonilla, B Kini, A Mathews, H Mohideen, N Norton, J Parthasarathy, M Petrowsky, C Rodriguez, T Senitzer, D Shanti, S Stiff, P Toor, A
source	PMC
abstract	Murine studies using anti-T-cell antibodies for conditioning in allogeneic SCT demonstrate engraftment with low rates of GVHD. On the basis of this preclinical model, we conditioned 30 patients with advanced hematologic malignancies with rabbit antithymocyte globulin (ATG) and TBI, to reduce rates of fatal acute GVHD. Patients were enrolled in two sequential groups: cohort 1 received ATG 10 mg/kg in divided doses (days −4 to −1)+200 cGy TBI (n=16), and cohort 2 received ATG (days −10 to −7)+450 cGy TBI (n=14). Median donor blood chimerism for the combined group was 94, 93 and 93% in the first, second and third months after transplant. Only three developed grade II acute GVHD despite 43% of patients receiving unrelated donor transplants. One-year survival was 71±11 and 54±14%, respectively, in recipients of related and unrelated donor SCT. Donor lymphocyte infusions were needed in 12 patients for the management of relapse and for mixed donor–recipient chimerism in 4 patients. We conclude that 10 mg/kg ATG and TBI allows engraftment with a low risk of acute GVHD; however, further dose optimization of ATG is required to achieve a balance between GVHD and disease relapse.
has issue date	2008-08-18(xsd:dateTime)
bibo:doi	10.1038/bmt.2008.244
bibo:pmid	18711352
has license	no-cc
sha1sum (hex)	dcc27e479115365accb550f7a525d3a8471c1a9c
schema:url	https://doi.org/10.1038/bmt.2008.244
resource representing a document's title	Feasibility of conditioning with thymoglobulin and reduced intensity TBI to reduce acute GVHD in recipients of allogeneic SCT
has PubMed Central identifier	PMC7101790
has PubMed identifier	18711352
schema:publication	Bone Marrow Transplant
resource representing a document's body	covid:dcc27e479115365accb550f7a525d3a8471c1a9c#body_text
is schema:about of	named entity 'patients' named entity 'hematologic malignancies' named entity 'GVHD' named entity 'grade II' named entity 'TBI' named entity 'ALLOGENEIC' named entity 'DOSES' named entity 'RISK OF' named entity 'T-CELL' named entity 'CHIMERISM' named entity 'SECOND' named entity 'GVHD' named entity 'chimerism' named entity 'ATG' named entity 'acute' named entity 'donor' named entity 'chimerism' named entity 'ATG' named entity 'antibodies' named entity 'GVHD' named entity 'ATG' named entity 'GVHD' named entity 'antithymocyte globulin' named entity 'relapse' named entity 'ATG' named entity 'thymoglobulin' named entity 'ATG' named entity 'conditioning' named entity 'immunostimulatory' named entity 'chimerism' named entity 'relapse' named entity 'relapse' named entity 'Chicago' named entity 'TBI' named entity 'thymic involution' named entity 'elimination half-life' named entity 'DLI' named entity 'blood donor' named entity 'GVHD' named entity 'CD8' named entity 'liver enzyme elevation' named entity 'phase II studies' named entity 'ATG' named entity 'GVHD' named entity 'IFN-g' named entity 'refractory' named entity 'multiple myeloma' named entity 'CD3' named entity 'solid organ' named entity 'TBI' named entity 'prognosis' named entity 'chimeric' named entity 'CsA' named entity 'murine' named entity 'thymic' named entity 'CD16' named entity 'Disease-specific' named entity 'lymphocyte' named entity 'Beckman Coulter Inc.' named entity 'DLI' named entity 'MHC' named entity 'T-cell depletion' named entity 'relapse' named entity 'flow cytometer' named entity 'TBI' named entity 'murine' named entity 'chemotherapy' named entity 'allografts'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software